Telix Pharmaceuticals (STU:T3X) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:T3X Telix Pharmaceuticals Ltd STU:T3X
55 GF Score
Price €9.24
GF Value €25.65
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

STU:T3X
55GF Score
Telix Pharmaceuticals Ltd STU:T3X
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Telix Pharmaceuticals (STU:T3X) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of €9.24 is trading 64% below its estimated GF Value™ of €25.65. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:T3X:

  • FFO:
  • GF Value™: €25.65 vs. price of €9.24 (64% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the STU:T3X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
55GF Score

Get the complete analysis for STU:T3X

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.24
Price
€25.65
GF Value